{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:37:23Z","timestamp":1790552243943,"version":"4.1.0"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["K08HL107450-01"],"award-info":[{"award-number":["K08HL107450-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01 HL128734-01A1"],"award-info":[{"award-number":["R01 HL128734-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1U19AI109662"],"award-info":[{"award-number":["1U19AI109662"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI057229"],"award-info":[{"award-number":["U19AI057229"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U54I117925"],"award-info":[{"award-number":["U54I117925"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Pulmonary arterial hypertension (PAH) is characterized by progressive narrowing of pulmonary arteries, resulting in right heart failure and death. BMPR2 (bone morphogenetic protein receptor type 2) mutations account for most familial PAH forms whereas reduced BMPR2 is present in many idiopathic PAH forms, suggesting dysfunctional BMPR2 signaling to be a key feature of PAH. Modulating BMPR2 signaling is therapeutically promising, yet how BMPR2 is downregulated in PAH is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We intended to identify and pharmaceutically target BMPR2 modifier genes to improve PAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We combined siRNA high-throughput screening of &amp;gt;20,000 genes with a multicohort analysis of publicly available PAH RNA expression data to identify clinically relevant BMPR2 modifiers. After confirming gene dysregulation in tissue from patients with PAH, we determined the functional roles of BMPR2 modifiers in vitro and tested the repurposed drug enzastaurin for its propensity to improve experimental pulmonary hypertension (PH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>We discovered FHIT (fragile histidine triad) as a novel BMPR2 modifier. BMPR2 and FHIT expression were reduced in patients with PAH. FHIT reductions were associated with endothelial and smooth muscle cell dysfunction, rescued by enzastaurin through a dual mechanism: upregulation of FHIT as well as miR17-5 repression. Fhit\u2212\/\u2212 mice had exaggerated hypoxic PH and failed to recover in normoxia. Enzastaurin reversed PH in the Sugen5416\/hypoxia\/normoxia rat model, by improving right ventricular systolic pressure, right ventricular hypertrophy, cardiac fibrosis, and vascular remodeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights the importance of the novel BMPR2 modifier FHIT in PH and the clinical value of the repurposed drug enzastaurin as a potential novel therapeutic strategy to improve PAH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201712-2553oc","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T17:02:43Z","timestamp":1534266163000},"page":"83-98","source":"Crossref","is-referenced-by-count":45,"title":["<i>FHIT<\/i>\n                    , a Novel Modifier Gene in Pulmonary Arterial Hypertension"],"prefix":"10.1093","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-4378","authenticated-orcid":false,"given":"Svenja","family":"Dannewitz Prosseda","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine"},{"name":"Wall Center for Pulmonary Vascular Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Tian","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine"},{"name":"Wall Center for Pulmonary Vascular Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kuramoto","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine"},{"name":"Wall Center for Pulmonary Vascular Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boehm","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine"},{"name":"Wall Center for Pulmonary Vascular Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Sudheendra","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Wall Center for Pulmonary Vascular Disease"},{"name":"Cardiovascular Institute"},{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Wall Center for Pulmonary Vascular Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Solow-Cordero","sequence":"additional","affiliation":[{"name":"High-Throughput Bioscience Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Saldivar","sequence":"additional","affiliation":[{"name":"Chemical and Systems Biology, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Austin","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Loyd","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Andruska","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Donato","sequence":"additional","affiliation":[{"name":"Biomedical Informatics Research\u2013Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine"},{"name":"Wall Center for Pulmonary Vascular Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Huebner","sequence":"additional","affiliation":[{"name":"Molecular Genetics and Cancer Biology Program, Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross J.","family":"Metzger","sequence":"additional","affiliation":[{"name":"Wall Center for Pulmonary Vascular Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purvesh","family":"Khatri","sequence":"additional","affiliation":[{"name":"Biomedical Informatics Research\u2013Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edda","family":"Spiekerkoetter","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine"},{"name":"Wall Center for Pulmonary Vascular Disease"},{"name":"Cardiovascular Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,1]]},"reference":[{"key":"2026030321233941500_bib1","first-page":"1993","article-title":"Heritable pulmonary arterial hypertension","author":"Austin","year":"2002"},{"key":"2026030321233941500_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-\u03b2 receptor, cause familial primary pulmonary hypertension","volume":"26","author":"Lane","year":"2000","journal-title":"Nat Genet"},{"key":"2026030321233941500_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4103\/2045-8932.87293","article-title":"The genetics of pulmonary arterial hypertension in the post-BMPR2 era","volume":"1","author":"Fessel","year":"2011","journal-title":"Pulm Circ"},{"key":"2026030321233941500_bib4","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/01.CIR.0000012754.72951.3D","article-title":"Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor","volume":"105","author":"Atkinson","year":"2002","journal-title":"Circulation"},{"key":"2026030321233941500_bib5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1378\/chest.10-1269","article-title":"Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice","volume":"139","author":"Rich","year":"2011","journal-title":"Chest"},{"key":"2026030321233941500_bib6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"2026030321233941500_bib7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/CIRCRESAHA.111.300483","article-title":"Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation","volume":"112","author":"Long","year":"2013","journal-title":"Circ Res"},{"key":"2026030321233941500_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.201801-0062UP","article-title":"Update in pulmonary vascular disease 2016 and 2017","volume":"198","author":"Brittain","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321233941500_bib9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1164\/rccm.201611-2273LE","article-title":"Hypermethylation of BMPR2 promoter occurs in patients with heritable pulmonary arterial hypertension and inhibits BMPR2 expression","volume":"196","author":"Liu","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321233941500_bib10","doi-asserted-by":"crossref","first-page":"1602449","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321233941500_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1164\/rccm.201411-2061LE","article-title":"Low-dose FK506 (tacrolimus) in end-stage pulmonary arterial hypertension","volume":"192","author":"Spiekerkoetter","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321233941500_bib12","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J Clin Invest"},{"key":"2026030321233941500_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1146\/annurev.genet.32.1.7","article-title":"The role of the FHIT\/FRA3B locus in cancer","volume":"32","author":"Huebner","year":"1998","journal-title":"Annu Rev Genet"},{"key":"2026030321233941500_bib14","first-page":"2121","article-title":"Association between cigarette smoking and FHIT gene alterations in lung cancer","volume":"57","author":"Sozzi","year":"1997","journal-title":"Cancer Res"},{"key":"2026030321233941500_bib15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mc.20122","article-title":"Expression of common chromosomal fragile site genes, WWOX\/FRA16D and FHIT\/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR","volume":"44","author":"Thavathiru","year":"2005","journal-title":"Mol Carcinog"},{"key":"2026030321233941500_bib16","first-page":"7","article-title":"Immunohistochemical characterization of FHIT expression in normal human tissues","volume":"8","author":"Kujan","year":"2016","journal-title":"Interv Med Appl Sci"},{"key":"2026030321233941500_bib17","first-page":"5032","article-title":"Loss of FHIT function in lung cancer and preinvasive bronchial lesions","volume":"58","author":"Sozzi","year":"1998","journal-title":"Cancer Res"},{"key":"2026030321233941500_bib18","first-page":"3866","article-title":"FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease","volume":"59","author":"Campiglio","year":"1999","journal-title":"Cancer Res"},{"key":"2026030321233941500_bib19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/modpathol.3800081","article-title":"Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer","volume":"17","author":"Toledo","year":"2004","journal-title":"Mod Pathol"},{"key":"2026030321233941500_bib20","first-page":"179698","article-title":"Fragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocarcinoma cells by blocking PI3K-Akt pathway","volume":"2014","author":"Huang","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"2026030321233941500_bib21","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026030321233941500_bib22","first-page":"A4228","article-title":"Enzastaurin reverses pulmonary arterial hypertension by targeting the novel BMPR2 modifier FHIT [abstract]","volume":"195","author":"Dannewitz Prosseda","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321233941500_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2042-6410-3-6","article-title":"BMPR2 expression is suppressed by signaling through the estrogen receptor","volume":"3","author":"Austin","year":"2012","journal-title":"Biol Sex Differ"},{"key":"2026030321233941500_bib24","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1084\/jem.20122709","article-title":"A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation","volume":"210","author":"Khatri","year":"2013","journal-title":"J Exp Med"},{"key":"2026030321233941500_bib25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/nar\/gkw797","article-title":"Methods to increase reproducibility in differential gene expression via meta-analysis","volume":"45","author":"Sweeney","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2026030321233941500_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40478-014-0093-y","article-title":"Integrated multi-cohort transcriptional meta-analysis of neurodegenerative diseases","volume":"2","author":"Li","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"2026030321233941500_bib27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2010.11","article-title":"Lck is a key target of imatinib and dasatinib in T-cell activation","volume":"24","author":"Lee","year":"2010","journal-title":"Leukemia"},{"key":"2026030321233941500_bib28","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"2026030321233941500_bib29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/humu.20922","article-title":"Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele","volume":"30","author":"Hamid","year":"2009","journal-title":"Hum Mutat"},{"key":"2026030321233941500_bib30","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1164\/rccm.201106-1130OC","article-title":"Altered microRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8","volume":"184","author":"Drake","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321233941500_bib31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/ATVBAHA.109.202028","article-title":"Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline","volume":"30","author":"Caruso","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026030321233941500_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molmed.2016.11.005","article-title":"Targeting vascular remodeling to treat pulmonary arterial hypertension","volume":"23","author":"Thompson","year":"2017","journal-title":"Trends Mol Med"},{"key":"2026030321233941500_bib33","first-page":"542","article-title":"New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension","volume":"57","author":"Hislop","year":"1976","journal-title":"Br J Exp Pathol"},{"key":"2026030321233941500_bib34","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/CIRCULATIONAHA.113.006167","article-title":"Role for DNA damage signaling in pulmonary arterial hypertension","volume":"129","author":"Meloche","year":"2014","journal-title":"Circulation"},{"key":"2026030321233941500_bib35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1164\/rccm.201411-2128OC","article-title":"Increased mutagen sensitivity and DNA damage in pulmonary arterial hypertension","volume":"192","author":"Federici","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321233941500_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1083\/jcb.200806049","article-title":"Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt\u2013\u03b2-catenin and Wnt\u2013RhoA\u2013Rac1 pathways","volume":"184","author":"de Jesus Perez","year":"2009","journal-title":"J Cell Biol"},{"key":"2026030321233941500_bib37","doi-asserted-by":"crossref","first-page":"e90427","DOI":"10.1172\/jci.insight.90427","article-title":"Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension","volume":"2","author":"Chen","year":"2017","journal-title":"JCI Insight"},{"key":"2026030321233941500_bib38","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1073\/pnas.080063497","article-title":"Muir\u2013Torre-like syndrome in Fhit-deficient mice","volume":"97","author":"Fong","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030321233941500_bib39","doi-asserted-by":"crossref","first-page":"10250","DOI":"10.1073\/pnas.191345898","article-title":"The tumor spectrum in FHIT-deficient mice","volume":"98","author":"Zanesi","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030321233941500_bib40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature07005","article-title":"The branching programme of mouse lung development","volume":"453","author":"Metzger","year":"2008","journal-title":"Nature"},{"key":"2026030321233941500_bib41","first-page":"3401","article-title":"The murine Fhit locus: isolation, characterization, and expression in normal and tumor cells","volume":"58","author":"Pekarsky","year":"1998","journal-title":"Cancer Res"},{"key":"2026030321233941500_bib42","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","article-title":"Formation of plexiform lesions in experimental severe pulmonary arterial hypertension","volume":"121","author":"Abe","year":"2010","journal-title":"Circulation"},{"key":"2026030321233941500_bib43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1164\/rccm.200703-499OC","article-title":"Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension","volume":"177","author":"Meyrick","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321233941500_bib44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.stem.2016.08.019","article-title":"Patient-specific iPSC-derived endothelial cells uncover pathways that protect against pulmonary hypertension in BMPR2 mutation carriers","volume":"20","author":"Gu","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2026030321233941500_bib45","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1183\/09031936.05.00045705","article-title":"Autoimmunity and pulmonary hypertension: a perspective","volume":"26","author":"Nicolls","year":"2005","journal-title":"Eur Respir J"},{"key":"2026030321233941500_bib46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","article-title":"Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension","volume":"115","author":"Rabinovitch","year":"2014","journal-title":"Circ Res"},{"key":"2026030321233941500_bib47","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/CIRCULATIONAHA.114.013317","article-title":"Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension","volume":"131","author":"Hemnes","year":"2015","journal-title":"Circulation"},{"key":"2026030321233941500_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cancergencyto.2010.01.019","article-title":"Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer","volume":"199","author":"Silva Soares","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"2026030321233941500_bib49","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JTO.0b013e318244aed0","article-title":"Inactivation of both FHIT and p53 cooperate in deregulating proliferation-related pathways in lung cancer","volume":"7","author":"Andriani","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2026030321233941500_bib50","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(02)00931-2","article-title":"FHIT: from gene discovery to cancer treatment and prevention","volume":"3","author":"Pekarsky","year":"2002","journal-title":"Lancet Oncol"},{"key":"2026030321233941500_bib51","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/cas.12887","article-title":"Exome-wide single-base substitutions in tissues and derived cell lines of the constitutive Fhit knockout mouse","volume":"107","author":"Paisie","year":"2016","journal-title":"Cancer Sci"},{"key":"2026030321233941500_bib52","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1378\/chest.09-2962","article-title":"Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study","volume":"138","author":"Schiess","year":"2010","journal-title":"Chest"},{"key":"2026030321233941500_bib53","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/35106058","article-title":"FRA3B and other common fragile sites: the weakest links","volume":"1","author":"Huebner","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"2026030321233941500_bib54","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/0008-5472.CAN-10-2360","article-title":"HIF-1\u03b1 confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function","volume":"71","author":"Yoo","year":"2011","journal-title":"Cancer Res"},{"key":"2026030321233941500_bib55","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/sj.onc.1204243","article-title":"Induction of the common fragile site FRA3B does not affect FHIT expression","volume":"20","author":"Michael","year":"2001","journal-title":"Oncogene"},{"key":"2026030321233941500_bib56","doi-asserted-by":"crossref","first-page":"e0131940","DOI":"10.1371\/journal.pone.0131940","article-title":"Inactivation of p53 is sufficient to induce development of pulmonary hypertension in rats","volume":"10","author":"Jacquin","year":"2015","journal-title":"PLoS One"},{"key":"2026030321233941500_bib57","doi-asserted-by":"crossref","first-page":"19303","DOI":"10.1038\/srep19303","article-title":"The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review","volume":"6","author":"Yan","year":"2016","journal-title":"Sci Rep"},{"key":"2026030321233941500_bib58","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1100\/tsw.2010.110","article-title":"FHIT: doubts are clear now","volume":"10","author":"Wali","year":"2010","journal-title":"Sci World J"},{"key":"2026030321233941500_bib59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/mc.20100","article-title":"Hypermethylation patterns in the Fhit regulatory region are tissue specific","volume":"43","author":"Guler","year":"2005","journal-title":"Mol Carcinog"},{"key":"2026030321233941500_bib60","first-page":"3429","article-title":"Methylation of the 5\u2032 CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas","volume":"58","author":"Tanaka","year":"1998","journal-title":"Cancer Res"},{"key":"2026030321233941500_bib61","first-page":"3581","article-title":"5\u2032 CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer","volume":"61","author":"Z\u00f6chbauer-M\u00fcller","year":"2001","journal-title":"Cancer Res"},{"key":"2026030321233941500_bib62","first-page":"2890","article-title":"Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer","volume":"8","author":"Yang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2026030321233941500_bib63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1476-4598-3-33","article-title":"CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in granulosa cell tumors (GCTs) of ovarian origin","volume":"3","author":"Dhillon","year":"2004","journal-title":"Mol Cancer"},{"key":"2026030321233941500_bib64","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1093\/carcin\/bgh217","article-title":"Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung","volume":"25","author":"Kim","year":"2004","journal-title":"Carcinogenesis"},{"key":"2026030321233941500_bib65","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.bjc.6605818","article-title":"Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules","volume":"103","author":"K\u00f6rner","year":"2010","journal-title":"Br J Cancer"},{"key":"2026030321233941500_bib66","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.febslet.2012.05.049","article-title":"MicroRNA-100 regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells by targeting BMPR2","volume":"586","author":"Zeng","year":"2012","journal-title":"FEBS Lett"},{"key":"2026030321233941500_bib67","doi-asserted-by":"crossref","first-page":"e83067","DOI":"10.1371\/journal.pone.0083067","article-title":"Role of miR-17 family in the negative feedback loop of bone morphogenetic protein signaling in neuron","volume":"8","author":"Sun","year":"2013","journal-title":"PLoS One"},{"key":"2026030321233941500_bib68","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/CIRCRESAHA.109.197491","article-title":"Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3\u2013microRNA cluster 17\/92 pathway","volume":"104","author":"Brock","year":"2009","journal-title":"Circ Res"},{"key":"2026030321233941500_bib69","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1172\/JCI32503","article-title":"An antiproliferative BMP-2\/PPAR\u03b3\/apoE axis in human and murine SMCs and its role in pulmonary hypertension","volume":"118","author":"Hansmann","year":"2008","journal-title":"J Clin Invest"},{"key":"2026030321233941500_bib70","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1093\/eurheartj\/ehs060","article-title":"AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension","volume":"35","author":"Brock","year":"2014","journal-title":"Eur Heart J"},{"key":"2026030321233941500_bib71","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cmet.2015.03.010","article-title":"BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension","volume":"21","author":"Diebold","year":"2015","journal-title":"Cell Metab"},{"key":"2026030321233941500_bib72","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J Clin Invest"},{"key":"2026030321233941500_bib73","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1164\/rccm.201003-0491OC","article-title":"Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension","volume":"182","author":"Aldred","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321233941500_bib74","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.canlet.2009.10.017","article-title":"Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation","volume":"291","author":"Cirombella","year":"2010","journal-title":"Cancer Lett"},{"key":"2026030321233941500_bib75","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1165\/rcmb.2013-0100OC","article-title":"Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension","volume":"49","author":"Drake","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026030321233941500_bib76","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1096\/fj.201500040","article-title":"Novel role for p56\/Lck in regulation of endothelial cell survival and angiogenesis","volume":"30","author":"Betapudi","year":"2016","journal-title":"FASEB J"},{"key":"2026030321233941500_bib77","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1158\/1541-7786.MCR-13-0386-T","article-title":"Fhit regulates EMT targets through an EGFR\/Src\/ERK\/Slug signaling axis in human bronchial cells","volume":"12","author":"Joannes","year":"2014","journal-title":"Mol Cancer Res"},{"key":"2026030321233941500_bib78","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/onc.2009.418","article-title":"Fhit regulates invasion of lung tumor cells","volume":"29","author":"Joannes","year":"2010","journal-title":"Oncogene"},{"key":"2026030321233941500_bib79","doi-asserted-by":"crossref","first-page":"e1004652","DOI":"10.1371\/journal.pgen.1004652","article-title":"FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs","volume":"10","author":"Suh","year":"2014","journal-title":"PLoS Genet"},{"key":"2026030321233941500_bib80","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1183\/09031936.00130809","article-title":"Distinct patterns of circulating endothelial cells in pulmonary hypertension","volume":"36","author":"Smadja","year":"2010","journal-title":"Eur Respir J"},{"key":"2026030321233941500_bib81","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1086\/678508","article-title":"The Sugen 5416\/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up","volume":"4","author":"Vitali","year":"2014","journal-title":"Pulm Circ"},{"key":"2026030321233941500_bib82","doi-asserted-by":"crossref","first-page":"L363","DOI":"10.1152\/ajplung.00212.2011","article-title":"The monocrotaline model of pulmonary hypertension in perspective","volume":"302","author":"Gomez-Arroyo","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026030321233941500_bib83","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1161\/HYPERTENSIONAHA.116.07353","article-title":"Metformin reverses development of pulmonary hypertension via aromatase inhibition","volume":"68","author":"Dean","year":"2016","journal-title":"Hypertension"},{"key":"2026030321233941500_bib84","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/nm.3695","article-title":"Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension","volume":"20","author":"Savai","year":"2014","journal-title":"Nat Med"},{"key":"2026030321233941500_bib85","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10637-012-9850-6","article-title":"Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics","volume":"31","author":"Nwankwo","year":"2013","journal-title":"Invest New Drugs"},{"key":"2026030321233941500_bib86","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/COC.0b013e31821cfc41","article-title":"Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma","volume":"35","author":"Schmidinger","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"2026030321233941500_bib87","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00280-001-0386-2","article-title":"Antiangiogenic effects of a protein kinase C\u03b2-selective small molecule","volume":"49","author":"Teicher","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026030321233941500_bib88","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood-2006-08-042747","article-title":"Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)","volume":"109","author":"Podar","year":"2007","journal-title":"Blood"},{"key":"2026030321233941500_bib89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"2026030321233941500_bib90","doi-asserted-by":"crossref","first-page":"18981","DOI":"10.1073\/pnas.0605821103","article-title":"FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells","volume":"103","author":"Bianchi","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030321233941500_bib91","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1074\/jbc.M806638200","article-title":"Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions","volume":"284","author":"Pichiorri","year":"2009","journal-title":"J Biol Chem"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/199\/1\/83\/67113909\/ajrccm_199_1_83.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/199\/1\/83\/67113909\/ajrccm_199_1_83.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:23:57Z","timestamp":1772591037000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/199\/1\/83\/8496718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,1]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201712-2553oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2019,1,1]]}}}